Scientists in Germany claim to have developed a nasal vaccine that successfully shuts down Covid-19 infections in the nose and throat. In hamster experiments, two doses of the weakened but live coronavirus created "sterilizing immunity" and prevented illness, achieving what has been a long-sought goal during the pandemic.
The new approach mimics the natural process of infection and closely resembles how the human immune system fights off viruses. Unlike current vaccines that focus on just the spike proteins, this nasal vaccine previews the entire virus for the body to recognize and respond to.
Trials in hamsters have shown promising results, with the vaccine outperforming mRNA-based and adenovirus-facilitated alternatives in creating an effective immune response. Researchers believe that boosting mucosal immunity by enhancing defenses in upper airways may be crucial in preventing Covid-19 infections.
The study began in 2021, before the Omicron variant emerged, so the initial vaccine was designed with the original strain of coronavirus. However, it still performed better against the newer variant than its competitors. Further human trials are necessary to confirm these findings and to assess the vaccine's efficacy.
At least four nasal vaccines for Covid-19 have reached late-stage testing in humans, according to the World Health Organization's tracker. While some may be nearing completion, others face challenges, such as high production costs and skepticism from experts about their effectiveness.
Developing a vaccine that induces mucosal immunity β boosting defenses in upper airways where the virus enters the body β could prove crucial in preventing future Covid-19 outbreaks. Scientists like Dr. Emanuel Wyler emphasize the importance of investing in this type of vaccine to combat new variants.
However, nasal vaccines also pose challenges due to their live nature, which means they can only be used by healthy individuals and not those with compromised immunity. "Although it's strongly attenuated, it's still a real virus," Dr. Wyler said.
The potential for a pan-coronavirus vaccine that induces mucosal immunity has sparked renewed interest in this approach, as researchers continue to explore new strategies to combat the ongoing pandemic.
The new approach mimics the natural process of infection and closely resembles how the human immune system fights off viruses. Unlike current vaccines that focus on just the spike proteins, this nasal vaccine previews the entire virus for the body to recognize and respond to.
Trials in hamsters have shown promising results, with the vaccine outperforming mRNA-based and adenovirus-facilitated alternatives in creating an effective immune response. Researchers believe that boosting mucosal immunity by enhancing defenses in upper airways may be crucial in preventing Covid-19 infections.
The study began in 2021, before the Omicron variant emerged, so the initial vaccine was designed with the original strain of coronavirus. However, it still performed better against the newer variant than its competitors. Further human trials are necessary to confirm these findings and to assess the vaccine's efficacy.
At least four nasal vaccines for Covid-19 have reached late-stage testing in humans, according to the World Health Organization's tracker. While some may be nearing completion, others face challenges, such as high production costs and skepticism from experts about their effectiveness.
Developing a vaccine that induces mucosal immunity β boosting defenses in upper airways where the virus enters the body β could prove crucial in preventing future Covid-19 outbreaks. Scientists like Dr. Emanuel Wyler emphasize the importance of investing in this type of vaccine to combat new variants.
However, nasal vaccines also pose challenges due to their live nature, which means they can only be used by healthy individuals and not those with compromised immunity. "Although it's strongly attenuated, it's still a real virus," Dr. Wyler said.
The potential for a pan-coronavirus vaccine that induces mucosal immunity has sparked renewed interest in this approach, as researchers continue to explore new strategies to combat the ongoing pandemic.